Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is delighted to announce the release of the next iteration of the SuperHuman antibody discovery platform, version 3.0.
The new release is a Single Light Chain (SLiC) library. This library can be used to easily generate bi-specific antibodies that share a common light chain, using the knob-and-hole IgG bi-specific technology. Our light chain is the most abundant and highly thermostable human framework, IGKV1-39 (15% of all human antibodies), with germline L1 and L2, and a “SuperPublic” L3 that represents the most common VJ rearrangement and is found frequently in all humans. The heavy chain consists of multiple optimized fully human frameworks with no mutations outside of the CDRs and only natural variation found in healthy human subjects in the CDRs, making it the most non-immunogenic platform available anywhere.
As part of Distributed Bio’s revolutionary business model partners of Distributed Bio now have access not only to this library, but also SuperHuman 1.0 and 2.0. By continuously refreshing the diversity and designs of the SuperHuman platform Distributed Bio ensures its partners stay on the leading edge of antibody therapeutic development with access to unparalleled diversity, engineering flexibility, and functional fitness.
“At Distributed Bio we are never satisfied. We constantly iteratively improve our technologies, focusing on increasing the developability of our leads to ensure that the best possible medicines reach patients, and increasing the diversity and engineering flexibility of our libraries so that we can target rare epitopes and rare biology that other technologies have failed to tackle. Challenging targets like GPCRs, Ion channels, TCR-like pMHC binders, rare mouse/primate/human epitopes, and conditional binders are routinely targeted with our technologies, delivering hits in many useful formats like IgGs, nanobodies, and CARs. Now with SuperHuman 3.0, we can add routine bi-specific discovery to our engineering repertoire,” says Jacob Glanville, Co-Founder and Chief Executive Officer of Distributed Bio. “We’ve analyzed hundreds of experiments with our machine learning AbGenesis platform to continuously improve the rules of making exceptional therapeutic repertoires. In 3 years we’ve built SuperHuman 1.0, 2.0 and now 3.0. We believe this is unparalleled in our industry and sets a new standard for antibody discovery companies. Even as 3.0 is released to our partners we are working on even more exciting technologies that will ultimately benefit all of us as patients.”
In 2018, Distributed Bio entered into an exclusive partnership with Charles River, a leading provider of essential products and services for pharmaceutical and biotechnology companies, government agencies and leading academic institutions. “Distributed Bio’s library of highly diverse antibodies enables our clients to progress their programs more quickly and seamlessly from hit to clinical candidate,” said Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River. “SuperHuman 3.0, coupled with the extensive capabilities of Charles River, creates a truly unparalleled end-to-end platform for therapeutic antibody discovery programs.”
About Distributed Bio
Distributed Bio is a computational immunoengineering biotechnology group, self-funded by licensing a stack of technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.
From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, sanger sequence, and functional assay without requiring large datacenter investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman antibody discovery platform. SuperHuman overcomes many of the limitation of other monoclonal generation technologies with an unprecedented diversity and developable fitness that has resulted in a unique engineering opportunity: a library that can generate thousands of unique and developable hits against every antigen tested, enabling routine success against targets that used to be nearly insurmountable – GPCRs, Ion Channels, pMHC complexes, broadly-neutralizing antibodies against HIV, therapeutic anti-idiotypic antibodies, bi-epitopic antibodies, and mouse/NHP/human cross-reactive antibodies.